Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Subject Areas on Research
-
"Me-too" products--friend or foe?
-
10 questions about statins and stroke.
-
2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque.
-
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
-
2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.
-
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
-
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
-
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
-
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
-
A Randomized Controlled Trial of Statins to Reduce Inflammation in Unruptured Cerebral Aneurysms.
-
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?
-
A protocol to evaluate the efficacy, perceptions, and cost of a cholesterol packaging approach to improve medication adherence.
-
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
-
A review of decision aids to assess cardiovascular risk.
-
A system to monitor statin-induced myopathy in individual engineered skeletal muscle myobundles.
-
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
-
A victory for statins or a defeat for diet policies? Cholesterol falls in Poland in the past decade: A modeling study.
-
ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells.
-
ACP Journal Club. ACC/AHA Pooled Cohort Risk Equations predicted 5-y risk for CV events in adults considered for statin initiation.
-
ACTIVE or not, high intensity is here to stay.
-
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
-
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
-
Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians.
-
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
-
Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.
-
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
-
Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
-
Advances in prevention and health services delivery 2009.
-
Advances in stroke: Prevention and health services delivery 2012-2013.
-
Adverse Effects of Statins.
-
Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial).
-
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.
-
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
-
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
-
An assessment by the Statin Cognitive Safety Task Force: 2014 update.
-
An assessment by the Statin Intolerance Panel: 2014 update.
-
An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System.
-
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
-
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
-
Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events.
-
Application of new cholesterol guidelines to a population-based sample.
-
Application of the new cholesterol guidelines.
-
Assessing the Impact of Coronary Plaque on the Relative and Absolute Risk Reduction With Statin Therapy.
-
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association.
-
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
-
Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study.
-
Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system.
-
Association between statin use and uveitis: results from the Pacific Ocular Inflammation study.
-
Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.
-
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
-
Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial.
-
Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription.
-
Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound.
-
Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement.
-
Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study.
-
Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines.
-
Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
-
Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
-
Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study.
-
Associations among statins, preventive care, and prostate cancer mortality.
-
Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
-
Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients.
-
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
-
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
-
Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
-
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
-
Atorvastatin-induced hemorrhagic cystitis: a case report.
-
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
-
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
-
Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial.
-
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
-
Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients.
-
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
-
Benefit versus risk in statin treatment.
-
Benefits of Bempedoic Acid - Clearer Now.
-
Can group medical clinics improve lipid management in diabetes?
-
Canadian stroke best practice consensus statement: Secondary stroke prevention during pregnancy.
-
Cardiovascular Disease Prevention: Risk Assessment.
-
Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications.
-
Cardiovascular Risk in the Lung Cancer Screening Population: A Multicenter Study Evaluating the Association Between Coronary Artery Calcification and Preventive Statin Prescription.
-
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
-
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
-
Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.
-
Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.
-
Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry.
-
Cholesterol rethink for high-risk patients.
-
Chronic kidney disease and stroke.
-
Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study.
-
Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues.
-
Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies.
-
Clinical application of cardiovascular pharmacogenetics.
-
Clinical reasoning and prevention of cardiovascular disease.
-
Co-occurring reasons for medication nonadherence within subgroups of patients with hyperlipidemia.
-
Coenzyme Q10 and statins in heart failure: the dog that didn't bark.
-
Cognitive and Physical Function by Statin Exposure in Elderly Individuals Following Acute Myocardial Infarction.
-
Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not?
-
Combination lipid therapy: could teamwork make the dream work?
-
Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
-
Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool.
-
Community pharmacists' experience with pharmacogenetic testing.
-
Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke.
-
Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.
-
Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®).
-
Confirmation of Statin and Fibrate Use from Small-Volume Archived Plasma Samples by High-Throughput LC-MS/MS Method.
-
Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study.
-
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
-
Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study.
-
Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
-
Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals.
-
Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
-
Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases.
-
Deep thoughts on lipids and cognition.
-
Design considerations for an integrated microphysiological muscle tissue for drug and tissue toxicity testing.
-
Determining When to Add Nonstatin Therapy: A Quantitative Approach.
-
Discontinuation of statins in routine care settings.
-
Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.
-
Drug therapy increases bone density in osteonecrosis of the femoral head in canines.
-
Dual hepatic metabolism of cerivastatin--clarifications.
-
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
-
Early statin initiation and outcomes in patients with acute coronary syndromes.
-
Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction.
-
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
-
Effect of HMG CoA reductase inhibitors on the development of chronic lung allograft dysfunction.
-
Effect of High-Dose Simvastatin on Cerebral Blood Flow and Static Autoregulation in Subarachnoid Hemorrhage.
-
Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
-
Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.
-
Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.
-
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
-
Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure.
-
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
-
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
-
Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
-
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
-
Effect of simvastatin on retinal vascular caliber: the Age-Related Maculopathy Statin Study.
-
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
-
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
-
Effect of statin use on incidence of eczema and atopic dermatitis: A retrospective cohort study.
-
Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
-
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
-
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
-
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
-
Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.
-
Effects of cardiovascular medications on rate of functional decline in Alzheimer disease.
-
Effects of cholesterol-lowering statins on the aqueous humor outflow pathway.
-
Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS).
-
Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.
-
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.
-
Effects of perioperative statin use on cardiovascular complications in patients submitted to non-cardiac surgery: protocol for a systematic review, meta-analysis, and trial sequential analysis.
-
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials.
-
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
-
Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.
-
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
-
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
-
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.
-
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
-
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
-
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
-
Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.
-
Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins.
-
Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs.
-
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome.
-
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
-
Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease.
-
Evaluation of a packaging approach to improve cholesterol medication adherence.
-
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial.
-
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
-
Expression quantitative trait locus analysis identifies novel genes for statin myopathy.
-
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
-
Ezetimibe plus a Statin after Acute Coronary Syndromes.
-
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy.
-
Familial hypercholesterolemia: Detect, treat, and ask about family.
-
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
-
Fluvastatin downregulates VEGF-A expression in TNF-α-induced retinal vessel tortuosity.
-
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
-
Focusing on inflammation in the treatment of atherosclerosis.
-
Frequency of Disparities in Laboratory Testing After Statin Initiation in Subjects ≥65 Years.
-
From the editor: Lessons from the East.
-
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.
-
Geosocial Factors Associated With Adherence to Statin Medications.
-
Guideline Recommendations for Statin Therapy-Reply.
-
Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
-
Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of age.
-
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
-
Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis.
-
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.
-
Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review.
-
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
-
High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.
-
High-dose atorvastatin after stroke or transient ischemic attack.
-
High-dose statins in acute coronary syndromes.
-
Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality.
-
Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography.
-
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
-
Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome.
-
Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease.
-
ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research.
-
Imagine all the people...
-
Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.
-
Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.
-
Impact of Medicaid preferred drug lists on therapeutic adherence.
-
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
-
Impact of lipid-lowering medications and low-density lipoprotein levels on 1-year clinical outcomes after coronary artery bypass grafting.
-
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
-
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.
-
Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST).
-
Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction.
-
Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
-
Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin.
-
Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles.
-
In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.
-
In patients at high CV risk receiving simvastatin, the Myopathy Risk Score predicted statin-related myopathy.
-
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.
-
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.
-
Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018.
-
Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.
-
Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease.
-
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
-
Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry.
-
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
-
Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.
-
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
-
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.
-
Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia.
-
Intradiscal injection of simvastatin results in radiologic, histologic, and genetic evidence of disc regeneration in a rat model of degenerative disc disease.
-
Invited commentary.
-
Is it time to reconsider combination lipid therapy in high-risk diabetic patients?
-
JCL roundtable: Lipid treatment targets.
-
JUPITER and the world of stroke medicine.
-
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
-
Letter by goldstein regarding article, "statins and intracerebral hemorrhage".
-
Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
-
Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction.
-
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
-
Lipid Testing and Statin Dosing After Acute Myocardial Infarction.
-
Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach.
-
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
-
Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry.
-
Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease.
-
Lipids, statins, and clinical outcomes in heart failure: rethinking the data.
-
Long-term adherence with cardiovascular drug regimens.
-
Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
-
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
-
Lovastatin-induced cytoskeletal reorganization in lens epithelial cells: role of Rho GTPases.
-
Low LDL cholesterol, statins, and brain hemorrhage: should we worry?
-
Low-density lipoprotein cholesterol level and statin use among Medicare beneficiaries with diabetes mellitus.
-
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
-
Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins.
-
Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI.
-
Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
-
Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.
-
Management of hyperlipidemia in older adults.
-
Medication Discontinuation in the IMPROVE-IT Trial.
-
Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans.
-
Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance.
-
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.
-
Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment.
-
Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial.
-
Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains.
-
Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review.
-
Modeling statin myopathy in a human skeletal muscle microphysiological system.
-
Modern medical management of acute ischemic stroke.
-
Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction.
-
National trends and disparities in statin use for ischemic heart disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey.
-
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
-
No effect of low-dose statins treatment on cerebral blood flow in humans with atherosclerotic cerebrovascular disease.
-
Non-cholinergic strategies for treating and preventing Alzheimer's disease.
-
Novel application of approaches to predicting medication adherence using medical claims data.
-
Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States.
-
Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development.
-
Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.
-
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
-
PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.
-
Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
-
Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry.
-
Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care.
-
Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial.
-
Patterns and predictors of discharge statin prescription among hospitalized patients with intracerebral hemorrhage.
-
Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness.
-
Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
-
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.
-
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
-
Pharmacogenomics of β-blockers and statins: possible implications for perioperative cardiac complications.
-
Pharmacometabolomics Meets Genetics: A "Natural" Clinical Trial of Statin Effects.
-
Pharmacometabolomics of statin response.
-
Phenotype standardization for statin-induced myotoxicity.
-
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
-
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database
-
Potential role for statins in sickle cell disease.
-
Preeclampsia: animal models for a human cure.
-
Preexisting statin use is associated with greater reperfusion in hyperacute ischemic stroke.
-
Preoperative statin therapy does not reduce cognitive dysfunction after cardiopulmonary bypass.
-
Prevalence of apparent treatment-resistant hypertension among individuals with CKD.
-
Prevention and health services delivery.
-
Prevention and health services delivery.
-
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
-
Prevention of cardiovascular disease: time for a course correction.
-
Primary prevention and statins: is it just about going to class?
-
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease.
-
Protein prenylation: unique fats make their mark on biology.
-
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.
-
Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.
-
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
-
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
-
Reader response: Association of statin use with spontaneous intracerebral hemorrhage: A cohort study.
-
Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke.
-
Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.
-
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
-
Registry Evidence for Modulation of the Acute Ischemic Heart Disease Pathway: Statins Prevent Heart Failure?
-
Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
-
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
-
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
-
Reply: High-Dose Statins Increase Adverse Events and Do Not Improve Survival.
-
Retrospective analysis of bovine pericardium (Vascu-Guard) for patch closure in carotid endarterectomies.
-
Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
-
Review: In noncardiac surgery, amiodarone, β-blocker, or statin prophylaxis reduces postoperative AF.
-
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease.
-
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
-
Risk of cerebral vasopasm after subarachnoid hemorrhage reduced by statin therapy: A multivariate analysis of an institutional experience.
-
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
-
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
-
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
-
Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007.
-
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
-
Role of small GTP-binding proteins in lovastatin-induced cataracts.
-
SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.
-
SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care.
-
SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation.
-
Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.
-
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
-
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.
-
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
-
Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database.
-
Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.
-
Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease.
-
Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.
-
Should Cardiovascular Preventive Therapy Be Over-the-Counter?
-
Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?
-
Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
-
Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage.
-
Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis.
-
Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial.
-
Simvastatin suppresses cyclophosphamide-induced changes in urodynamics and bladder inflammation.
-
Simvastatin treatment duration and cognitive preservation in experimental subarachnoid hemorrhage.
-
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.
-
Statin Adherence: Does Gender Matter?
-
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
-
Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry).
-
Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.
-
Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study.
-
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
-
Statin intolerance in a referral lipid clinic.
-
Statin intolerance: more questions than answers.
-
Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke.
-
Statin safety: an assessment using an administrative claims database.
-
Statin therapy and inflammation in patients with diabetes treated with high dose aspirin.
-
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.
-
Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin.
-
Statin therapy inhibits fatty acid synthase via dynamic protein modifications.
-
Statin therapy reduces growth of abdominal aortic aneurysms.
-
Statin therapy should be discontinued in patients with intracerebral hemorrhage.
-
Statin therapy--Part II: Clinical considerations for cardiovascular disease.
-
Statin therapy--time to turn the focus from efficacy to implementation?
-
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
-
Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer's disease: a pilot observational study.
-
Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
-
Statin use and need for therapy in chronic lymphocytic leukemia.
-
Statin use and sex-specific stroke outcomes in patients with vascular disease.
-
Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS).
-
Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer.
-
Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy.
-
Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
-
Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease.
-
Statin-associated memory loss: analysis of 60 case reports and review of the literature.
-
Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.
-
Statins after intracerebral hemorrhage: to treat or not to treat.
-
Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION.
-
Statins and age-related macular degeneration: time for a randomized controlled trial?
-
Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease.
-
Statins and cancer risk: what do we know and where do we go from here?
-
Statins and cognition: what can we learn from existing randomized trials?
-
Statins and delirium during critical illness: a multicenter, prospective cohort study.
-
Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis.
-
Statins and ischemic stroke severity: cytoprotection.
-
Statins and nitric oxide donors affect thrombospondin 1-induced chemotaxis.
-
Statins and other cholesterol-lowering medications and the presence of glaucoma.
-
Statins and poststroke intracerebral hemorrhage: Concern but increasing reassurance.
-
Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack.
-
Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.
-
Statins at Dialysis Transition-Supportive but Not Sufficient.
-
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants.
-
Statins do not affect platelet inhibition with clopidogrel during coronary stenting.
-
Statins for Primary Prevention in Older Adults: An Unresolved Conundrum.
-
Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out.
-
Statins for stroke prevention.
-
Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence.
-
Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach.
-
Statins in acute brain injury: getting the cart before the horse.
-
Statins in adult patients with HIV: Protocol for a systematic review and network meta-analysis.
-
Statins in traumatic brain injury.
-
Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response.
-
Statins, exercise, and skeletal muscle.
-
Statins--is there potential for uncovering new benefits (or detriments)?
-
Statistical analysis plan for the control of blood pressure and risk attenuation-rural Bangladesh, Pakistan, Sri Lanka (COBRA-BPS) trial: a cluster randomized trial for a multicomponent intervention versus usual care in hypertensive patients.
-
Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study.
-
Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure).
-
Taking a longer term view of cardiovascular risk: the causal exposure paradigm.
-
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
-
The ASCEND-ND trial: study design and participant characteristics.
-
The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events trial: To continue or not? How to answer the question.
-
The Benefit Model for Prevention of Cardiovascular Disease: An Opportunity to Harmonize Guidelines.
-
The Burden of Polypharmacy in Patients Near the End of Life.
-
The CHD challenge: comparing four cost-effectiveness models.
-
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
-
The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?
-
The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering.
-
The Importance of Considering Clinical Inertia and Implementation Science When Addressing Medication Adherence.
-
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
-
The association of pre- and posthospital medication adherence in myocardial infarction patients.
-
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.
-
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II.
-
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
-
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
-
The clopidogrel-statin interaction.
-
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The dichotomous role of nitric oxide in the pathogenesis of accelerated atherosclerosis associated with systemic lupus erythematosus.
-
The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk.
-
The effect of statin use and intensity on stroke and myocardial infarction after carotid endarterectomy.
-
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
-
The effects of statins on blood pressure in normotensive or hypertensive subjects--a meta-analysis of randomized controlled trials.
-
The impact of manufacturer coupon use in the statin market.
-
The influence of oral statin medications on progression of glaucomatous visual field loss: A propensity score analysis.
-
The influence of statin medications on prostate-specific antigen levels.
-
The polypill to prevent cardiovascular disease: physicians' perspectives.
-
The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?
-
The quest for the "Holy Grail" of ischemic stroke cytoprotection: Statins may not be the answer.
-
The truth and consequences of the COURAGE trial.
-
Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus.
-
Therapy and clinical trials.
-
Therapy and clinical trials.
-
Therapy and clinical trials.
-
Therapy and clinical trials.
-
Therapy and clinical trials.
-
Time to Revisit Using 10-Year Risk to Guide Statin Therapy.
-
Toxicity of oxidized low density lipoproteins for vascular smooth muscle cells and partial protection by antioxidants.
-
Translating evidence into practice: use of statins in real-world patients with heart failure.
-
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
-
Trends in statin utilisation in US adults with non-alcoholic fatty liver disease.
-
Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry.
-
US Surveillance of Acute Ischemic Stroke Patient Characteristics, Care Quality, and Outcomes for 2019.
-
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
-
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation.
-
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).
-
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
-
Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all.
-
Using pharmacogenetics to improve drug safety and efficacy.
-
Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
-
Valvular heart disease.
-
Was the role of statins in slowing the progression of abdominal aortic aneurysms underestimated?
-
Who Will Own the Responsibility to Prescribe Statins? Tragedy of the Commons.
-
Keywords of People
-
-
James, Michael Lucas,
Professor of Anesthesiology,
Anesthesiology
-
Laskowitz, Daniel Todd,
Professor of Neurology,
Duke Science & Society
-
Moorman, Patricia Gripka,
Professor Emeritus in Family Medicine and Community Health,
Duke Cancer Institute
-
Muir, Kelly Walton,
Associate Professor of Ophthalmology,
Ophthalmology, Glaucoma
-
O'Connor, Christopher Michael,
Adjunct Professor in the Department of Medicine,
Medicine, Clinical Pharmacology
-
Stinnett, Sandra Sue,
Associate Professor of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics